Nasdaq:US$13.48 (+0.09) | HKEX:HK$21.45 (+0.10) | AIM:£2.06 (+0)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.